ADMA Biologics Reports 14% Revenue Growth to $121.98 Million in Latest Quarter

ADMA Biologics, Inc. reported significant financial growth in its latest quarterly filing, with revenues reaching $121.98 million for the three months ended June 30, 2025, a 14% increase from $107.19 million in the same period last year. The company attributed this growth primarily to increased sales volume of its intravenous immune globulin product, ASCENIV, which has seen heightened acceptance among physicians, patients, and payers. Net income for the quarter was $34.22 million, slightly up from $32.06 million in the prior year, maintaining a basic earnings per share of $0.14.

In comparison to the previous fiscal period, ADMA's financial performance showed marked improvement. For the six months ended June 30, 2025, total revenues were $236.79 million, a 25% increase from $189.07 million in the same period of 2024. The gross profit also rose significantly to $128.32 million, up from $96.56 million, reflecting a gross margin improvement from 51.1% to 54.2%. The company’s operational expenses increased, with selling, general, and administrative expenses rising to $46.29 million from $32.25 million, largely due to higher compensation costs associated with increased headcount.

Strategically, ADMA has made notable advancements, including the FDA's approval of a yield enhancement production process for ASCENIV and BIVIGAM, which is expected to increase production efficiency and revenue potential. The company also acquired real estate in Boca Raton, Florida, for $12.6 million to expand its production capabilities. Additionally, ADMA has initiated a share repurchase program, authorizing up to $500 million in stock buybacks, with 816,237 shares repurchased at an average price of $18.35 during the second quarter.

Operationally, ADMA has expanded its plasma collection capabilities, operating ten FDA-licensed plasma collection centers across the U.S. The company reported a significant increase in accounts receivable, which rose to $109.73 million from $50 million, indicating strong sales but also highlighting the need for effective cash flow management. The company’s total assets increased to $558.38 million, up from $488.68 million at the end of 2024, while total liabilities also rose to $160.06 million from $139.66 million, reflecting ongoing investments in growth.

Looking ahead, ADMA remains optimistic about its growth trajectory, bolstered by the recent FDA approvals and strategic investments. The company anticipates continued revenue growth driven by ASCENIV and plans to further develop its product pipeline. However, it acknowledges potential risks, including reliance on third-party suppliers and the need for ongoing regulatory compliance, which could impact future operations and financial performance.